Andrew Metry
YOU?
Author Swipe
View article: Cost‐effectiveness analysis of the geko™ device (an <scp>NMES</scp> technology) in managing venous leg ulcers in <scp>UK</scp> healthcare settings
Cost‐effectiveness analysis of the geko™ device (an <span>NMES</span> technology) in managing venous leg ulcers in <span>UK</span> healthcare settings Open
This study evaluates the cost‐effectiveness of the geko device a neuromuscular electro‐stimulator technology with standard of care (SoC) versus SoC alone for venous leg ulcer (VLU) treatment, from the UK National Health Service (NHS) persp…
View article: Cost-effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare setting
Cost-effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare setting Open
Objective This study evaluates the cost-effectiveness of the geko device a neuromuscular electro-stimulator (NMES) technology with standard of care versus standard of care alone for venous leg ulcers treatment, from the UK National Health …
View article: PB1532 How Can We Improve Recruitment to Trials for Prevention of Venous Thromboembolism during Pregnancy and the Puerperium? A Qualitative Evaluation of the Patients' Perspective
PB1532 How Can We Improve Recruitment to Trials for Prevention of Venous Thromboembolism during Pregnancy and the Puerperium? A Qualitative Evaluation of the Patients' Perspective Open
Conclusion(s):Assessment of changes in hemostasis in the pregnant women undergoing IVF methods and using LMWH during the pregnancy and postpartum period might be useful for the individual evaluation of the termination of such anticoagulant…
View article: 264 Observational Study of Clinical Impact of E-Scooter Injuries at Major Trauma Centre
264 Observational Study of Clinical Impact of E-Scooter Injuries at Major Trauma Centre Open
Aim Is to focus on frequency E-scooter associated injuries especially open fractures and to see its burden on health system. Method Data of E-scooter injuries was extracted from trauma database from November 2017 to July 2022. Outcome meas…
View article: Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis
Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis Open
Background Severe acute respiratory syndrome coronavirus 2 is the virus that causes coronavirus disease 2019. Over six million deaths worldwide have been associated with coronavirus disease 2019. Objective To assess the cost-effectiveness …
View article: Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis
Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis Open
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19), which at the time of writing (January 2021) was responsible for more than 2.25 million deaths worldwide a…
View article: Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT Open
Background Licensed ranibizumab (0.5 mg/0.05 ml Lucentis ® ; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea ® ; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin ® ; F. H…
View article: Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis
Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis Open
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019. At the time of writing (October 2020), the number of cases of COVID-19 had been approaching 38 million and more than…